Abstract
Diabetic retinopathy is the leading cause of blindness in developed countries. Diabetic macular edema (DME) is the most frequent cause of vision loss in patients with type 2 diabetes. Steroids may reduce the concentration of inflammatory cytokines and growth factors, and have effect on increased vascular permeability. Topical steroids does not reach intraocular therapeutic concentrations and periocular injection requires frequent injections at the risk of complications. Systemic administration of steroids may be useful, but high doses are required and are associated with severe systemic side effects. Intravitreal injection of steroids provides a powerful therapeutic effect, but it is associated with frequent secondary cataracts and increased IOP. The need for repeated injections may increase the risks associated with the injection procedure. Preliminary studies have proved the possibility of implanting sustained release inserts in the vitreous body, allowing for therapeutic levels of steroids in the vitreous cavity and retina for more than six months. The advantages of these systems are to keep a stable and sustained concentration of the drug with higher therapeutic efficacy thus reducing the number of injections. However, the complications associated with the use of steroids such as cataracts and high IOP are very common.
Keywords: Diabetic macular edema, Intravitreal triamcinolone, Dexamethasone inserts, Drug delivery system, Fluocinolone, inserts, Steroids.
Current Diabetes Reviews
Title: Intravitreal Inserts of Steroids to Treat Diabetic Macular Edema
Volume: 5 Issue: 1
Author(s): Javier A. Montero and Jose M. Ruiz-Moreno
Affiliation:
Keywords: Diabetic macular edema, Intravitreal triamcinolone, Dexamethasone inserts, Drug delivery system, Fluocinolone, inserts, Steroids.
Abstract: Diabetic retinopathy is the leading cause of blindness in developed countries. Diabetic macular edema (DME) is the most frequent cause of vision loss in patients with type 2 diabetes. Steroids may reduce the concentration of inflammatory cytokines and growth factors, and have effect on increased vascular permeability. Topical steroids does not reach intraocular therapeutic concentrations and periocular injection requires frequent injections at the risk of complications. Systemic administration of steroids may be useful, but high doses are required and are associated with severe systemic side effects. Intravitreal injection of steroids provides a powerful therapeutic effect, but it is associated with frequent secondary cataracts and increased IOP. The need for repeated injections may increase the risks associated with the injection procedure. Preliminary studies have proved the possibility of implanting sustained release inserts in the vitreous body, allowing for therapeutic levels of steroids in the vitreous cavity and retina for more than six months. The advantages of these systems are to keep a stable and sustained concentration of the drug with higher therapeutic efficacy thus reducing the number of injections. However, the complications associated with the use of steroids such as cataracts and high IOP are very common.
Export Options
About this article
Cite this article as:
Montero A. Javier and Ruiz-Moreno M. Jose, Intravitreal Inserts of Steroids to Treat Diabetic Macular Edema, Current Diabetes Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339909787314211
DOI https://dx.doi.org/10.2174/157339909787314211 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion
Vascular Disease Prevention (Discontinued) Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Current Management of Extracranial Carotid Artery Disease
Reviews on Recent Clinical Trials Impact of Omega-3 and Trans Fatty Acids on Vascular Remodeling:Opposing Roles in Cardiovascular Health
Current Enzyme Inhibition Drug Delivery to the Back of the Eye Following Topical Administration: An Update on Research and Patenting Activity
Recent Patents on Drug Delivery & Formulation An update on the Management and Treatment of Deep Vein Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Single Nucleotide Polymorphism and Serum Levels of VEGFR2 are Associated With Age Related Macular Degeneration
Current Neurovascular Research Involvement of Coagulation and Hemostasis in Inflammatory Bowel Diseases
Current Vascular Pharmacology Application of Hydrogen in Ophthalmology
Current Pharmaceutical Design